Objectives. Autoantibodies characterizing certain forms of inflammatory myopathy, which are myositis-specific autoantibodies, are useful in the diagnosis and prediction of prognosis in DM/PM. This study aimed to identify a subset of DM patients who have anti-nuclear matrix protein 2 (anti-NXP-2) antibodies by using biotinylated recombinant proteins, and to clarify the clinical features of DM patients with these antibodies.
Introduction
The idiopathic inflammatory myopathies (IIMs) are a group of acquired, systemic autoimmune diseases that include PM, DM and inclusion body myopathies [1, 2] . Several myositis-specific autoantibodies (MSAs) that are associated with certain clinical forms of IIMs have been identified, and they are useful tools for predicting the prognosis of IIMs. For example, anti-melanoma differentiation-associated protein 5 (MDA5)-antibody-positive patients demonstrate rapid progressive interstitial lung disease (ILD) and anti-transcriptional intermediary factor 1 (TIF1)-g-antibody-positive patients are often complicated with cancer [3] . Recently anti-nuclear matrix protein 2 (anti-NXP-2, also called anti-MJ) antibodies that react to a 140-kDa polypeptide have been described in cohorts of JDM patients in the UK and Argentina [4] .
Anti-NXP-2 antibodies were reported to be associated with calcinosis, although the antibodies were investigated only in cohorts of juvenile patients [46] . The prevalences of anti-NXP-2 antibodies in adult patients with CTDs have been unknown. We hypothesized that anti-NXP-2 antibodies could be detected not only in JDM patients, but also in adult DM cases, and that these antibodies could be a new serological marker for a certain disease subset of adult DM. To investigate the presence of anti-NXP-2 antibodies in sera from patients with various CTDs, this study used our newly developed ELISAs and immunoprecipitation (IPP) with biotinylated recombinant protein. We clarified the prevalence of the antibodies against NXP-2 in adult DM and examined clinical features associated with anti-NXP-2 antibodies.
Materials and methods

Patients and sera
From the serum bank of the Department of Dermatology, Nagoya University Hospital, we used sera from 170 Japanese patients with CTDs. The CTD cohort consisted of 106 patients with DM [including 12 with JDM, 38 with clinically amyopathic DM (ADM) and 14 with cancerassociated DM], 8 with PM, 21 with SLE, 20 with SSc and 15 with myositis overlap syndrome ( Table 1) . The group of patients with myositis overlap syndrome consisted of seven patients with overlapping CTDs and eight with MCTD. Serum samples were collected at the time of diagnosis or before aggressive therapy. Twenty healthy Japanese individuals were also assessed as normal controls. All the DM patients, except those clinically ADM, and all the PM patients fulfilled Bohan and Peter's criteria [7, 8] . All the clinically ADM patients fulfilled Sontheimer's criteria [9] . The clinically ADM group included patients who had developed ILD within 6 months after disease onset. Patients were classified as having JDM if they were <16 years at the onset of DM according to the criteria of Bohan and Peter [10] . Patients were classified as cancer-associated DM if the internal malignancy was diagnosed within 3 years (before or after) of the DM diagnosis based on previous studies [11] . SLE was diagnosed by the ACR criteria for SLE [12] . SSc was diagnosed according to the SSc diagnostic criteria [13] established by the Ministry of Health, Labour and Welfare of Japan, which were modified from the ACR criteria [14] . MCTD was diagnosed according to the MCTD diagnostic criteria [15] . Patients were classified as having myositis in overlap with another CTD if they met published criteria for the CTD. The clinical records were retrospectively reviewed and the following information was recorded: demographic data including gender, age at onset, diagnosis, date of serum sampling and clinical features including the presence of cutaneous signs of DM (heliotrope rash or Gottron's papules), RP or calcinosis. Elevated creatine kinase (CK) was defined by elevation of CK above the normal range in clinical laboratory tests. Patients were diagnosed as having ILD, which was defined by fibrosis on chest radiographs or chest CT scans. Internal malignancy was investigated according to the results of whole-body CT, endoscopy, colonoscopy, gynaecological examination and breast cancer screening. The ages at the time of sera collection and gender ratios of each clinical group are summarized in Table 1 . In the juvenile-onset patients with DM, two patients were originally seen at other hospitals far outside our area but then transferred to our hospital. Their intervals between disease onset and serum sampling were 26 and 28 years. All the patients and healthy individuals in the present study gave fully informed consent for participation, including provision of serum samples. This study was approved by the Ethics Committee of Nagoya University Graduate School of Medicine and conducted in accordance with the Declaration of Helsinki.
ELISAs
Specific binding of serum antibodies to recombinant NXP-2 was analysed using direct solid-phase ELISA. This method was based on our previous protocol, which quantitatively measured the antibodies against MDA-5 [16] . Instead of a conventional optical system for ELISA, this study used a microplate luminometer to increase the sensitivity, thereby reducing the required amount of biotinylated recombinant protein for the assays. The full-length NXP-2 cDNA clone was purchased from Kazusa DNA Research Institute (Chiba, Japan) and its DNA sequences were confirmed to be identical to GenBank accession number D50926. Biotinylated recombinant NXP-2 was produced from the cDNA, using the TnT T7 Quick Coupled Transcription/Translation System (Promega, Madison, WI, USA) according to our protocol [3] . Nunc Immobilizer Streptavidin Plates (Thermo Scientific Nunc, Roskilde, Denmark) to which streptavidin was covalently coupled via a spacer were pre-washed three times with PBS containing 0.05% Tween-20 (T-PBS) and were coated with biotinylated recombinant NXP-2 diluted with T-PBS (50 ml/well) and incubated for 1 h at room temperature with gentle agitation. After three washes with T-PBS, the wells were blocked with 200 ml of a blocking buffer of 0.5% BSA (Wako, Osaka, Japan) in T-PBS for 1 h. Uncoated wells were used to measure the background levels for each sample. Diluted sample sera with blocking buffer (50 ml/well) were incubated for 1 h at room temperature, followed by incubation with anti-human IgG antibody conjugated with HRP (Dako, Glostrup, Denmark) as a secondary antibody (50 ml/well) at 1:30 000 dilution after five washes. After incubation for 1 h at room temperature, the plates were washed five times and incubated with SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo Scientific Pierce, Rockford, IL, USA) (50 ml/well) as the substrate according to the manufacturer's protocol. Then, the relative luminescence unit (RLU) was determined using the GloMax-Multi Detection System (Promega). Each serum sample was tested in duplicate, and the mean RLU subtracted background was used for data analysis. A standard curve was obtained from serial concentrations of a serum sample containing a high titre of the anti-NXP-2 antibody. The cut-off level was set at 17.0 U, based on 5 S.D. above the mean value obtained from 20 healthy control sera.
Detection of anti-NXP-2 antibodies using IPP IPP was performed using transcription and translation (TnT) products as previously described [1720], with minor modifications. Briefly, 10 ml of patient sera was mixed and incubated with 20 ml of a 50% slurry of Protein G Sepharose 4 Fast Flow (GE Healthcare, Buckinghamshire, UK) and 270 ml IPP buffer (PBS containing 1% Nonidet P-40) at 4 C for 1 h. Sepharose beads were mixed and incubated with 270 ml binding buffer (IPP buffer containing 0.5% BSA) and 10 ml of the TnT products, which was pre-cleared using the sepharose beads, at 4 C for 1 h. The beads were washed five times with IPP buffer, suspended in Laemmli sample buffer and the IgG-bound proteins retained by the sepharose beads were electrophoresed on 7.5% SDSPAGE gel. The proteins were electrophoretically transferred onto Immobilon-P transfer membranes (Millipore Corporation, Billerica, MA, USA) and the biotinylated proteins were subsequently detected with Western Blue Substrate (Promega). IIF IIF was performed by standard methods [21] using HEp-2 cells (Fluoro HEPANA Test; MBL, Nagoya, Japan).
Statistical analysis
The frequency of antibodies between each CTD and control was analysed using Fisher's exact test. The associations between clinical features and antibodies in DM were analysed using Fisher's exact test or unpaired Student's t-test. SPSS version 17.0 for Windows (SPSS Japan, Tokyo, Japan) was used to perform the statistical analysis. P < 0.05 was considered statistically significant.
Results
Establishment of ELISA with biotinylated recombinant NXP-2
For the screening of anti-NXP-2 antibodies in large numbers of serum samples, we established an ELISA system that uses biotinylated recombinant NXP-2. In the present study, by using a luminometer, we succeeded in decreasing the required amount of TnT product for the assay from 10 ml/well in the previous system to 1 ml/well in our newly developed system, based on the results of serial dilution experiments (data not shown). We screened a total of 170 serum samples obtained from patients with various CTDs. Based on the cut-off level (17.0) at 5 S.D. above the mean value, six patients with DM and one patient with PM were classified into the anti-NXP-2-positive group (Fig. 1) . When the cut-off was set at 3 S.D. above the mean value (9.7), one sample from a patient with SLE was just beneath the cut-off (9.2). Subsequently serum samples from these eight patients were used for IPP to confirm whether they were truly positive for the anti-NXP-2 antibodies.
Detection of anti-NXP-2 antibodies using IPP After the initial screening by ELISA we investigated antibodies against NXP-2 in sera from 7 anti-NXP-2-positive patients, 1 equivocal patient and 24 anti-NXP-2-negative patients for their ability to immunoprecipitate biotinylated recombinant NXP-2. Six of the seven anti-NXP-2-positive sera in ELISA showed a distinct protein band with a molecular weight of 140 kDa in IPP assays (Fig. 2, lanes 16 ). All were from patients with DM, whereas the serum from the one patient with PM did not react to the recombinant (Fig. 2, lane 7) . The serum from an SLE patient with an equivocal level of anti-NXP-2 antibodies in ELISA was negative in IPP (Fig. 2, lane 8) . Furthermore, anti-NXP-2 antibodies were not detected in normal control sera as well as 24 anti-NXP-2-negative sera in ELISA by IPP assays (representative negative sera, Fig. 2, lane 9) .
Clinical and serological features of DM patients with anti-NXP-2 antibodies Of the 106 DM sera, 6 (5.7%) had anti-NXP-2 antibodies (Table 1) . In contrast, anti-NXP-2 antibodies were not detected in any serum from patients with other CTDs.
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ELISA of anti-NXP-2 antibodies
Anti-NXP-2 antibodies were found at a higher frequency in DM patients than in patients with other CTDs (6/106 vs 0/64, P = 0.0844). Concerning JDM, only 1 (8.3%) of the 12 JDM patients had serum that reacted with NXP-2. The patient with anti-NXP-2 antibodies had no findings associated with calcinosis. As for adult DM, sera from 5 (5.3%) of 94 patients were positive. In adult cancerassociated DM, serum from 1 (7.1%) of 14 patients was positive for anti-NXP-2 antibodies. This patient had ovarian cancer that resulted in a fatal outcome. Adult patients with classical DM had anti-NXP-2 antibodies with a significantly higher frequency than patients with other CTDs (4/48 vs 0/64, P = 0.0313). Even if adult patients with cancer-associated DM were added to the classical adult DM group, a significant difference would still remain between adult patients with DM and patients with other CTDs (5/62 vs 0/64, P = 0.0265). According to these results, anti-NXP-2 antibodies were detected not only in JDM, but also in cancer-associated adult DM and classical adult DM. No patients with any other CTD, clinically ADM or healthy individuals had anti-NXP-2 antibodies. Table 2 compares the clinical features between anti-NXP-2-positive patients and anti-NXP-2-negative patients. There was little significant difference in gender, age at onset, diagnosis or prevalence of DM-specific skin symptoms (heliotrope rash and Gottron's papules or sign) and RP. All six of the anti-NXP-2-positive patients had myopathy, but none of them were complicated with ILD. The frequency of calcinosis was relatively higher in the positive group, although the difference was not significant. Table 3 summarizes the serological information of the six patients with anti-NXP-2 antibodies in the present study. IIF revealed diverse nuclear staining patterns with various titres in all the anti-NXP-2-positive sera. The IIF titres did not correspond well to the ELISA units.
Discussion
There is increasing evidence that MSAs are associated with clinical subsets of DM/PM. Several MSAs have shown positive polypeptide bands $140160 kDa on SDSPAGE by the traditional assay of IPP with cell extracts, including anti-NXP-2, anti-Mi-2, anti-MDA-5, anti-TIF1-g and anti-OJ antibodies. It is difficult to differentiate these antibodies by molecular weight. We used biotinylated recombinant proteins and successfully detected anti-MDA-5 and anti-TIF1-g antibodies in our IPP study [3] . However, there are technical limits to handling large numbers of serum samples efficiently with IPP. Thus we needed to establish an ELISA system. In our previous study, taking advantage of the high affinity between biotin FIG. 1 ELISA using biotinylated recombinant NXP-2 protein. Measurement of anti-NXP-2 antibodies in 170 serum samples from patients with various CTDs or 20 healthy control subjects. We used the 1 ml/well of TnT mixture and the diluted patient serum samples at 1:1000 for measuring all samples (closed circles). The antibody units were calculated from the RLU using a standard curve obtained from serial concentrations of a serum sample containing a high titre of the anti-NXP-2 antibody. Broken line indicates the cut-off value (17.0 U). Six samples from patients with DM, one sample from a patient with PM (grey circle, just around the cut-off value) and one sample from a patient with SLE (open circle, under the mean values of 20 healthy controls + 3 S.D.) were introduced to IPP assays with biotinylated recombinant proteins (see Fig. 2 and avidin, we used streptavidin-coated ELISA plates for simultaneous purification and immobilization of the biotinylated protein for the detection of anti-MDA-5 antibodies [16] . However, improving the sensitivity of the ELISA was required, because this ELISA system was not suitable for measuring large numbers of serum samples. The TnT system cannot produce a practical amount of recombinant proteins compared with the Escherichia coli expression system. In this study, we established highly sensitive ELISA with TnT products by using a luminometer.
This study examined the specificity of anti-NXP-2 antibodies in Japanese patients with DM. Anti-NXP-2 antibodies were finally detected in sera of 6 of 170 patients with CTDs by ELISA and IPP. We conclude that only the DM patients who screened positive by ELISA were confirmed to have anti-NXP-2 antibodies. The results of ELISA and IPP in this study with biotinylated recombinant NXP-2 were inconsistent with previously reported findings of anti-NXP-2 antibodies being detected in JDM patients, especially patients with calcinosis in Argentina and the UK [46], Espada et al. [5] reported that 25% of JDM patients were found to have anti-NXP-2 (anti-MJ) antibodies and that anti-NXP-2-positive juvenile patients demonstrated severe disease characterized by muscle atrophy with contractures. Some of them also had large-joint arthritis, dysphagia, cutaneous vasculitis and calcinosis universalis. Gunawardena et al. [6] showed that anti-140-kDa protein (NXP-2) antibodies were significantly associated with the presence of calcinosis when compared with the overall juvenile myositis cohort. In our study, only 1 (8.3%) of 12 JDM patients were anti-NXP-2 positive. The prevalence of other MSAs in our JDM patients was 42%, i.e. five patients with anti-TIF1-g antibodies (data not shown). The prevalence of anti-NXP-2 antibodies in JDM was low in our study, but this may depend on the fact that some patients had long periods (26 and 28 years) between onset and serum sampling. In contrast to adult DM, in which calcification is relatively uncommon, it is estimated that 2040% of JDM patients have calcification [22, 23] . In our study, 2 of the 12 JDM patients were complicated with calcinosis. Both patients were anti-TIF1-gantibody positive (data not shown).
Few reports have addressed the correlation between adult-onset DM and calcinosis. In our study, 4 (4.3%) of 94 adult DM patients had calcinosis. Among adult DM patients with calcinosis, only one patient (Patient 3 in Table 3 ) was detected as having anti-NXP-2 antibodies. She had additional anti-centromere antibodies (ACAs) and multiple cutaneous calcinosis. Although ACAs are known to be associated with calcinosis, it is not clear whether the Table 3 ) of the six patients had cancer. She was found to have ovarian cancer at the same time as being diagnosed with DM. Anti-TIF1-g antibodies, which had been associated with cancer in our previous study [3] , were not detected in her serum. The present findings suggest that DM patients who are anti-NXP-2 positive do not always have benign forms of DM, at least not adult patients, even when their myositis is moderate. One of the few published studies on anti-NXP-2 antibodies in adult DM patients is a preliminary report [24] . They reported that the frequency and clinical associations of anti-NXP-2 autoantibodies varied between adults and juveniles. By IIF, the staining patterns by anti-NXP-2-positive sera were mainly divided into speckled or diffuse. NXP-2, also called MORC3 (microrchidia family CW-type zinc finger 3), is a MORC-family protein that is characterized by three conserved domains consisting of RNA-binding, nuclear matrix-binding and coiled-coil domains [25] . They are structurally separated and they may have important roles in diverse nuclear functions, including regulation of transcription, maintenance of nuclear architecture and RNA metabolism. NXP-2 is a nuclear matrix protein that is shown as speckled-like staining in IIF. The nuclear staining of NXP-2 becomes diffuse after nuclear matrix treatment with RNase [25] . Nuclear domains, which are demonstrated as nuclear dots by anti-MORC3 antibodies in IIF [26] , were not clearly detected by patients' sera. The differences among IIF patterns in anti-NXP-2-positive patients might have resulted from other concomitant antibodies. It is also possible that altered conformational structures of NXP-2 affect the accessibility of antibodies to antigenic epitopes. In any case, IIF patterns are not useful for screening anti-NXP-2 antibodies.
The previously described DM-specific antigens, Mi-2 [27] and TIF1-g [28] are nuclear proteins that are also involved in transcriptional regulation. It is notable that antibodies to small ubiquitin-like modifier (SUMO) activating enzyme (SAE), which is involved in a post-transcriptional modification called sumoylation, have been recently described in adult DM [29] . NXP-2 was reported to be a target of SAE and to have a possible role in SUMOmediated transcriptional repression [30] . Mi-2 is also thought to be directly involved in mediating SUMOdependent repression [31] . TIF1-g is considered to act as a repressor of TGF-b superfamily-induced transcription via its E3 ubiquitin ligase activity [32] . The SUMO pathway may play a potential role in the pathogenic mechanisms of DM.
In summary, our newly developed ELISA is applicable for the measurement of anti-NXP-2 antibodies. Our present study revealed that anti-NXP-2 antibodies were observed not only in JDM but also in adult DM. Adult DM patients with anti-NXP-2 antibodies had uniformly moderate myositis without ILD, even though this serological group featured no major demographic differences with respect to the other adult DM patients in our study. To elucidate the characteristic clinical features and the prognosis of patients with anti-NXP-2 antibodies, a much larger cohort is needed, especially for adult patients.
Rheumatology key messages
. A newly established ELISA for biotinylated recombinant proteins is useful for detecting anti-NXP-2 antibodies. . Anti-NXP-2 antibodies are detected not only in JDM, but also in adult DM.
